T he vascular endothelium produces and releases vasoactive substances that appear to serve as important modulators of vascular tone.' In addition, the endothelium is believed to play a key role in the maintenance of a normal vascular structure and the prevention of atherosclerotic changes. Although the original view of the response-to-injury theory of atherogenesis was centered on the morphological integrity of the endothelium,2 it is now believed that the loss of normal endothelial function rather than endothelial denudation is pivotal in the development of early atherosclerotic changes.34 In line with this view is evidence in animals that alterations of endothelial function and morphological changes characteristic of atherosclerosis coincide.S Accordingly, changes in the endothelial con-trol of vascular tone may be markers of early or future atherosclerotic vascular changes in humans, a view that is supported by observations that the presence of risk factors for the development of atherosclerosis is associated with endothelial dysfunction. Thus, the vasodilator response to acetylcholine, which is mediated through endothelial release of endothelium-derived relaxing factor6 and has been linked to endothelial synthesis and release of nitric oxide,7 is impaired in the presence of hypercholesterolemia in human coronary8 as well as forearm9 resistance vessels in vivo. Arterial hypertension is also associated with a diminished vasodilator response to acetylcholine10l1 and an abnormality of basal nitric oxide-mediated dilation in forearm resistance vessels. 12 An impaired endothelial function has also been suggested in patients with diabetes mellitus. "3 Finally, in addition to a disturbance of endothelial vasodilator and antiplatelet mechanisms, the endothelial vasoconstrictor peptide endothelin-114 may be involved in the pathogenesis of atherosclerosis. 15, 16 Cigarette smoking is another important risk factor for the development of atherosclerosis,17-'9 and its effects on endothelial prostacyclin production and the vessel wall-platelet interaction have received considerable in- 
Preparations of Solutions for Infusions
All solutions were freshly prepared before each study. Endothelin-1 (Peptides International) and NG-monomethyl-Larginine (L-NMMA; Calbiochem AG) were diluted in Physiogel (gelatin solution 4%; MW, 22 000; Swiss Red Cross) to avoid binding to syringes or tubing. Infusions of Physiogel at volumes of up to 6 mL/min did not influence forearm blood flow to a measurable degree.25 Sodium nitroprusside was dissolved in 5% dextrose and protected from light. Norepinephrine (Dr G. Bichsel AG) and L-arginine (Hausmann AG) were dissolved in 0.9% saline. Intra-arterial infusions were performed with volumes between 0.15 and 0.8 mL/min for norepinephrine and sodium nitroprusside, respectively. For endothelin-1 and L-NMMA, volumes were hold constant at 2 mL/min and 1 mL/min, respectively, using a constant-speed infusion pump (Sage Instruments Inc).
Study Protocols
The studies started at 8:00 AM and lasted for approximately 5 to 6 hours. The subjects were supine in a quiet, airconditioned room with a constant temperature (200 to 22°C). 
Studies in Smokers
Because of the long duration of endothelin-1-induced vasoconstriction in the human forearm,2728 it was considered impossible to assess all aspects of the study in only one group of smokers. Accordingly, the effects of short-term smoking on endothelin-1-induced vasoconstriction and on nitric oxidemediated control of vascular tone were investigated in two groups.
Smoking and Endothelin-l-Induced Vasoconstriction
After measurement of baseline blood pressure, heart rate, and forearm blood flow, norepinephrine was infused in 11 smokers in three dosages (7.5, 20 , and 40 ng. min . 100 mL-1 forearm tissue) for 5 minutes each and forearm blood flow was recorded during the fifth minute of infusion. Approximately 20 minutes afterward, forearm blood flow had returned to basal values. Subsequently, endothelin-1 was infused in five increasing dosages (0.25, 0.5, 1.0, 25, and 50 ng * min . 100 mL-1 forearm tissue) for 5 minutes, and measurements of forearm blood flow were obtained during the last minute. After the dose-response curve to endothelin was completed, forearm blood flow was allowed to return to baseline values, which took approximately 90 minutes. Then baseline hemodynamic recordings were obtained, and the subjects asked to smoke two cigarettes within 15 minutes. Five minutes later, blood pressure, heart rate, and forearm blood flow were recorded, and arterial blood was collected for determination of plasma catecholamines. Next, norepinephrine infusions and hemodynamic measurements were repeated, and the subjects asked to smoke one additional cigarette in the middle of the 20-minute waiting period. Finally, endothelin-1 infusions and the respective measurements were repeated in an identical way.
To test for a possible nonspecific effect unrelated to shortterm smoking but rather to the long duration of the study, an identically timed drug infusion protocol was performed in 5 additional smokers who did not smoke before repeat infusions of norepinephrine and endothelin-1.
Smoking and Nitric Oxide-Mediated Control of Vascular Tone
After measurement of baseline blood pressure, heart rate, and forearm blood flow, we infused sodium nitroprusside (0.6 jg* min-1 *100 mL-1 forearm tissue) in 8 smokers for 2 minutes, and measurements were repeated in the last minute of the infusion. After forearm blood flow had returned to basal values, L-NMMA was infused in three dosages (50, 100, and 200 yg * minm-. 100 mL-1 forearm tissue) for 5 minutes each to inhibit nitric oxide synthesis,29 and hemodynamics were recorded during the fifth minute of each infusion. The dose of L-NMMA was based on previous studies in humans in which a brachial artery infusion of 100 ,ug* min1' *100 mL- 
Studies in Nonsmokers
Because the short-term effects of smoking were not assessed in the 16 nonsmoking subjects, all investigations could be performed during the same study. Two different sequences of drug administration were used. In 11 subjects, baseline measurements were obtained followed by withdrawal of blood for determination of baseline plasma catecholamine and cholesterol concentrations. Then sodium nitroprusside, L-NMMA, L-arginine, norepinephrine, and endothelin-1 were infused allowing appropriate time between infusions for forearm blood flow measurements to return to baseline. In the remaining 5 subjects, the order was changed to L-NMMA first, followed by L-arginine, sodium nitroprusside, norepinephrine, and endothelin-1. However, changing the order of administration of sodium nitroprusside and L-NMMA did not affect the changes of forearm blood flow for either compound. Accordingly, the results of all 16 nonsmokers were pooled for analysis.
Statistical Analysis
Results are expressed as mean+SD. ANOVA Smokers and nonsmokers had similar baseline forearm flow and resistance values ( Table 1 ). All pharmacological interventions were subjectively and objectively well tolerated, and none resulted in significant changes in blood pressure or heart rate, indicating a lack of systemic effect of the doses used. Thus, changes in forearm blood flow after a particular intervention directly reflected changes in vascular resistance attributable to its respective interference with the control of resistance vessel tone.
Brachial artery infusion of sodium nitroprusside increased forearm blood flow similarly in smokers (n= 13) from 2.55±0.50 to 11.90±5.49 mL min'-100 mLand in nonsmokers (n= 16) from 2.49 +0.59 to 12.2±4.45 mL min-l 100 mL-1, respectively. The vascular responses to norepinephrine and endothelin-1 are summarized in Fig 1. Norepinephrine caused comparable reductions in forearm blood flow in smokers and nonsmokers. Likewise, the higher doses of endothelin-1 resulted in equal degrees of vasoconstriction. However, although the smallest dose of endothelin-1 resulted in an increase in forearm blood flow (2.62±0.78 versus 3.20±0.68 mL * min-1* 100 mL-1, P<.01) in nonsmokers, it remained unchanged in smokers (2.70±0.60 versus 2.65 ±0.64 mL -min' -100 mLU'). When comparing the vasoconstrictor potency of the two substances on a molar basis, endothelin-1 was approximately 15 times more potent than norepinephrine.
Blockade of nitric oxide synthesis by L-NMMA had a significantly (P<.01) greater effect on nonsmokers than in smokers (Fig 2) Our data also provide indirect evidence for a disturbance of endothelial prostacyclin and/or endotheliumderived relaxing factor release on stimulation. Thus, the vasodilator response to low-dose endothelin-1 infusion, which has been related to endothelial release of both prostacyclin and endothelium-derived relaxing factor,33 was absent in smokers. Accordingly, the lack of vasodilator response to low-dose endothelin-1 infusion in smokers may represent a disturbed endothelial response of either or both endothelial vasodilating systems. The importance of prostacyclin in mediating this response in humans is stressed by the significant reduction, but not abolition, of endothelin-1-mediated forearm vasodilation after administration of acetylsalicylic acid. 34 The present results are in line with recent studies investigating the vascular effects of stimulating nitric oxide release in smokers. Thus, coronary vasodilation in response to muscarinergic stimulation23 and brachial artery dilation in response to increased flow24 were markedly impaired in smokers. Taken together, these data suggest an impairment of endothelial control of vascular tone both under basal conditions and during stimulation.
The disturbance of nitric oxide-mediated control of basal vascular tone did not result in a long-term increase in vascular resistance in our subjects, suggesting that other mechanisms compensate for the lack of nitric oxide-mediated vasodilation. Indeed, vascular tone may even be reduced as suggested by epidemiological data showing reduced basal blood pressure in smokers,3536 an observation consistent with the tendency of a lower systolic blood pressure in our smoking subjects. However, the mechanisms underlying this observation are not clear.
Smoking may also lead to a decrease in the antiatherogenic plasma high-density lipoprotein cholesterol fraction 2, and hypercholesterolemia is known to impair endothelial function.8,9 Our subjects had normal total and high-density plasma cholesterol concentrations. Therefore, this factor probably cannot account for 
Short-Term Effects of Smoking
Short-term smoking resulted in increases in heart rate and blood pressure,38,39 which have been attributed to both sympathoneuronal and sympathomedullary stimulation. 40 The concomitant rise in plasma epinephrine and systolic blood pressure in our study is compatible with this contention, whereas the lack of an increase in plasma norepinephrine and in diastolic pressure, also observed by others,3839 appears to disagree. This difference, however, may be related to the timing of blood sampling after smoking since plasma catecholamine concentrations were maximal at the end of a 10-minute smoking period40 and norepinephrine but not epinephrine concentrations declined within 10 minutes toward control values.40 Because we measured plasma catecholamines and blood pressure 5 minutes after smoking, this difference in timing may account for unchanged plasma norepinephrine concentrations and the small increase in diastolic compared with systolic blood pressure in our study. The dominance of sympathomedullary stimulation at the time of measurement through 132-adrenoceptor-mediated muscle vasodilation may also explain the unchanged forearm vascular resistance in our subjects after smoking. Repetitive increases of sympathetic tone in smokers may also participate in atherogenesis since the uptake of atherogenic low-density lipoprotein is accelerated by epinephrine and norepinephrine at pathophysiological blood concentrations.41 Short-term smoking did not affect the response to direct vascular muscle stimulation by sodium nitroprusside or blockade of nitric oxide synthesis by L-NMMA. The lack of an effect of short-term smoking on the vascular response to L-NMMA may appear surprising in view of the marked reduction of the basal L-NMMA effect in smokers. Possibly, the reduced L-NMMA response precludes further reductions after short-term smoking, or the cumulative impact of small and difficult-to-detect changes may be required for the development of the long-term disturbance of vascular response to L-NMMA. Letting nonsmokers smoke might answer this question, but the ethical limitations are obvious.
In contrast, the response pattern to endothelin-1 was changed: vasoconstriction was observed for the lowest dose, and the vasoconstrictor response to high doses was enhanced. We can only speculate about the underlying mechanisms, but a reduction of prostacyclin release after smoking22 might have unmasked the vasoconstrictor activity even of low-dose endothelin-1. A decreased endothelium-derived relaxing factor release may also be involved,33 but the unchanged response to L-NMMA after smoking argues somewhat against this possibility.
The enhanced vasoconstrictor response to endothelin-1 after smoking is not readily explained. In dogs, inhibition of endogenous nitric oxide synthesis augmented the vasoconstrictor property of endothelin-1,42 but short-term smoking did not change the effects of L-NMMA in our subjects. Moreover, the response to endothelin-1 was similar in smokers and nonsmokers, even though smokers had a reduced response to L-NMMA. Therefore, an altered balance between endothelium-derived vasodilating and vasoconstricting factors probably cannot explain our findings. Endothelin receptor stimulation is coupled to the phosphatidylinositol turnover pathway in an manner essentially similar to that of a1-adrenoceptors.4344 Therefore, increased adrenergic vasoconstriction or an interaction of adrenergic and endothelin-1-induced stimulation of the phosphatidylinositol pathway may be important in mediating the enhanced vascular effect of endothelin-1 after smoking, but the exact mechanism(s) of this finding remain unclear.
A comparison of the vascular effects of norepinephrine and endothelin-1 before smoking confirms the greater vasoconstrictor potency of endothelin-1 in vivo. Although the difference in potency was not as great as previously suggested,14 regional differences exist, with mesenteric and renal vessels being most sensitive. 45, 46 Methodological Considerations
We used L-NMMA as a tool to study endotheliumderived nitric oxide in humans. However, although L-NMMA inhibits nitric oxide synthesis in vitro,29 the acetylcholine-induced vascular relaxation was inhibited only by approximately 66%.30 Even though our highest dose of L-NMMA was twice that of the original study, we do not have data on the completeness of nitric oxide synthesis inhibition in our subjects. Recent data suggest that muscarinergic receptor subtypes selectively mediate the release of nitric oxide and a putative, prostanoid endothelium-derived hyperpolarizing factor.47 Therefore, although an incomplete blockade of vascular acetylcholine effects by L-NMMA may be due to incomplete blockade of nitric oxide synthesis, it may also relate to the release of endothelium-derived hyperpolarizing factor. However, acetylsalicylic acid did not change the vasodilator response to acetylcholine in humans,9,10 suggesting that prostanoid release may not contribute significantly to the effects of acetylcholine in the human forearm. Regardless of the mechanism underlying the incomplete blockade of vascular acetylcholine effects, the reduced L-NMMA response in smokers probably cannot be explained by nonmaximal inhibition of nitric oxide synthesis only. Thus, the total L-NMMA effect in smokers was observed with the smallest dose (Fig 2) . This contrasts with the finding in nonsmokers, in whom the L-NMMA response was dose dependent, and an additional effect of even higher doses of L-NMMA cannot be excluded. Such an effect, however, obviously would widen rather than narrow the gap between smokers and nonsmokers.
The decrease in forearm blood flow in response to L-NMMA infusion in our nonsmoking volunteers was somewhat greater than that in volunteers of previous studies (-54.2% versus -39.6%30 and -38%).32 This may be related to our use of a higher dose of L-NMMA30 and a different methodology for forearm blood flow measurement.32 Moreover, no information on the smoking status of the volunteers was provided in these studies, and the possible inclusion of smokers might also contribute to this difference.
We used norepinephrine infusions to control for an unspecific effect of smoking on vasoconstrictor stimuli. The reduced vasoconstrictor response to norepinephrine after smoking was unexpected but may be related to a reduced effect of exogenously administered norepinephrine in the presence of increased sympathetic stimulation and high a-adrenergic receptor occupancy by endogenous catecholamines.
The reproducible vasoconstrictor responses to norepinephrine and endothelin-1 in smokers who waited for a similar time span before repeat drug infusions but did not smoke make an unspecific, time-related effect an unlikely explanation for the changes in vascular responses to norepinephrine and endothelin-1 observed after short-term smoking.
Potential Implications
The role of endothelin-1 in the regulation of vascular tone under normal and pathophysiological conditions is not defined. Therefore, the meaning of the enhanced vasoconstrictor response to exogenously administered endothelin-1 after smoking is not clear. Moreover, it is obviously unknown whether this finding would also apply to endogenously released endothelin-1. However, a potentially negative effect is conceivable in situations where endothelin-1 may be involved in the regulation of vascular tone, eg, severe hypertension48 or congestive heart failure.49 Endothelin-1 may also play a role in the pathogenesis of coronary vasospasm.50,51 Because smoking has been identified as a strong risk factor for coronary vasospasm,52,53 it is tempting to speculate that smoking-induced enhancement of coronary vasoconstrictor effects of endothelin-1 may be causally involved. However, the introduction of endothelin-converting enzyme inhibitors or specific receptor antagonists has to be awaited to clarify such issues.
Endothelin-1 also has mitogenic activity15 and may be involved in the development of atherosclerotic vascular changes. 16 Whether smoking interferes with this effect has not been investigated.
Prostacyclin and endothelium-derived nitric oxide have synergistic effects, resulting in relaxation of vascular smooth muscle and inhibition of adhesion and aggregation of blood platelets.5455 These systems thereby represent an important endothelial defense mechanism against bloodborne cells and chemicals. Consequently, a disturbance of this defense mechanism may be an important factor leading to the chain of events that ultimately result in the development of atherosclerotic vascular changes.3 The reduced nitric oxide-dependent component of basal vascular tone and the impaired endothelium-dependent vasodilator response found in this and other studies23,24 in smokers may therefore not only reflect a functional defect of the endothelium related to the regulation of vascular tone but, more important, also indicate a loss of its normal antiatherosclerotic functions. Several lines of evidence suggest also that smoking interferes with prostacyclin metabolism. A reduction in prostacyclin production has been described in cultured endothelial cells20 and in the thoracic aorta of rats exposed to tobacco smoke,56 in umbilical arteries of babies born to smoking mothers,21 and in long-term smokers after smoking. 22 An increased urinary excretion of the prostacyclin metabolite 2,3-dinor-6-keto-prostaglandin-Fia together with an increase in thromboxane A2 metabolites in healthy, longterm smokers has been taken as an index £pr an enhanced platelet-vessel wall interaction.57 Although the increase in prostacyclin metabolites is not undisputed,58 the data are consistent with respect to an increase in platelet-derived thromboxane A2 metabolites indicating platelet activation in smokers. Thus, a weakening of the normal endothelial antiatherosclerotic defense line, as possibly reflected by the functional changes of the endothelium, together with smoking-induced platelet activation, enhanced endothelin-1-mediated vasoconstriction, and catecholamine-induced stimulation of atherogenic low-density lipoprotein uptake may ultimately contribute to the development of atherosclerotic vascular changes.
